Teclistamab pre-approval access in relapsed or refractory multiple myeloma.
Teclistamab will be administered subcutaneously (SC).
Other Name: JNJ-64007957
Must have relapsed/refractory multiple myeloma (RRMM) and have evidence of disease
progression after last therapy. Must have exhausted all available treatment options
accessible as local standard of care (example. proteasome inhibitors [PIs],
immunomodulatory imide drugs [IMIDs], anti CD38 monoclonal antibodies [mAbs] and therapies
targeting Exportin 1 [XPO1] and B cell maturation antigen [BCMA]). Must not be eligible for
a clinical trial with teclistamab or other medicines in this setting
Janssen Research & Development, LLC Clinical Trial
Janssen Research & Development, LLC